Joseph T Snodgrass

发表

Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.

Wei-Sheng Huang, Jan Romero, Shuangying Liu, 2011, Bioorganic & medicinal chemistry letters.

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.

Wei-Sheng Huang, Jan Romero, Shuangying Liu, 2010, Journal of medicinal chemistry.

Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).

T. Clackson, B. Druker, A. Corbin, 2007 .

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

T. Clackson, B. Druker, A. Corbin, 2009, Cancer cell.

9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.

G. Daley, T. Clackson, M. Azam, 2009, Journal of medicinal chemistry.

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.

T. Clackson, B. Druker, A. Corbin, 2006 .

Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.

T. Clackson, T. Sawyer, W. Shakespeare, 2008, Bioorganic & medicinal chemistry letters.

AP23848 against activation loop mutants of Kit In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and

B. Druker, M. Heinrich, T. Sawyer, 2013 .

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.

B. Druker, M. Heinrich, A. Corbin, 2005, Blood.

Structure-based design of AP23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy.

L. Rozamus, T. Clackson, R. Bohacek, 2004 .